Skip to Main Content

Author Details

Changmeng Cai
Center for Personalized Cancer Therapy, University of Massachusetts Boston
2006
53
28
PMIDPaper TitleJournal TitlePublished Year
36877164LSD1 Inhibition Disrupts Super-Enhancer-Driven Oncogenic Transcriptional Programs in Castration-Resistant Prostate Cancer.Cancer Res2023
37663929Demethylation of EHMT1/GLP Protein Reprograms Its Transcriptional Activity and Promotes Prostate Cancer Progression.Cancer Res Commun2023
37549269SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.Proc Natl Acad Sci U S A2023
35031563Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.Proc Natl Acad Sci U S A2022
36408179Increased <i>AR</i> expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2.Front Oncol2022
34975152RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.Oncogene2022
35121110Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer.Mol Ther2022
32946061Pioneer of prostate cancer: past, present and the future of FOXA1.Protein Cell2021
33632899Susceptibility-Associated Genetic Variation in <i>NEDD9</i> Contributes to Prostate Cancer Initiation and Progression.Cancer Res2021
32669350A Novel Mechanism to Induce BRCAness in Cancer Cells.Cancer Res2020
32868907Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer.Nat Genet2020
30718921TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells.Oncogene2019
31324883Forkhead domain mutations in FOXA1 drive prostate cancer progression.Cell Res2019
31428587LSD1 Activates PI3K/AKT Signaling Through Regulating p85 Expression in Prostate Cancer Cells.Front Oncol2019
31444154ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.Cancer Res2019
29059155Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.Oncogene2018
30012673BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.Cancer Res2018
28062857Positive feedback loop mediated by protein phosphatase 1α mobilization of P-TEFb and basal CDK1 drives androgen receptor in prostate cancer.Nucleic Acids Res2017
28465296Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.Mol Cancer Res2017
28916652LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression.Cancer Res2017
28036278A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer.Oncotarget2017
26936914ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.Clin Cancer Res2016
26636645Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation.Oncotarget2016
27760327Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein.Cell Rep2016
27043282SOX9 drives WNT pathway activation in prostate cancer.J Clin Invest2016
25320358Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.Clin Cancer Res2015
25808865PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy.Cancer Res2015
23752196Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis.Oncogene2014
25482560Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity.Cell Rep2014
24874833Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.Clin Cancer Res2014
24449822Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.Clin Cancer Res2014
23426182ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.J Clin Invest2013
25580383Androgen receptor epigenetics.Transl Androl Urol2013
23594111Discovery of a selective irreversible BMX inhibitor for prostate cancer.ACS Chem Biol2013
23716717Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases.Sci Signal2013
22174378Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer.Mol Endocrinol2012
23239736EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.Science2012
23023563In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.Mol Endocrinol2012
22275373Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.J Biol Chem2012
22139837Androgen Receptor Enhances p27 Degradation in Prostate Cancer Cells through Rapid and Selective TORC2 Activation.J Biol Chem2012
21712345Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy.Endocr Relat Cancer2011
22014572Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.Cancer Cell2011
21868758Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.Cancer Res2011
19491261Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2.Cancer Res2009
19584279Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castration-resistant prostate cancer.Cancer Res2009
18469090Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.J Mol Endocrinol2008
16964290Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation.Oncogene2007
17634427c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer.Mol Cancer Res2007
17505060ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion.Mol Endocrinol2007
17003774Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.Prostate Cancer Prostatic Dis2007
  • 1 - 50 of 53

Recommended Authors

Yuliang Wang
The Chinese University of Hong Kong
Career Start Year 2014
Number of shared co-authors 0
Xinpei Ci
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 14
Alec Paschalis
The Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 1
Ram S Mani
UT Southwestern Medical Center
Career Start Year 2008
Number of shared co-authors 6
Alastair Davies
University of British Columbia
Career Start Year 2008
Number of shared co-authors 11
Alfonso Urbanucci
Northwestern University Feinberg School of Medicine Chicago
Career Start Year 2008
Number of shared co-authors 11
Leigh Ellis
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Career Start Year 2007
Number of shared co-authors 23
Mark M Pomerantz
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 28
Mitchell G Lawrence
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 5
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 21
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 5
Charlie E Massie
University of Cambridge
Career Start Year 2003
Number of shared co-authors 2
Luke A Selth
Adelaide Medical School, University of Adelaide
Career Start Year 2002
Number of shared co-authors 10
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 24
David S Rickman
Meyer Cancer Center
Career Start Year 2001
Number of shared co-authors 7
Sooryanarayana Varambally
University of Alabama at Birmingham, USA O'Neal Comprehensive Cancer Center
Career Start Year 2001
Number of shared co-authors 4
Nadia Boufaied
Research Institute of the McGill University Health Centre
Career Start Year 2000
Number of shared co-authors 12
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 23
Jiaoti Huang
Duke University School of Medicine
Career Start Year 2000
Number of shared co-authors 15
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 16
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 8
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 14
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 12
Ian G Mills
Queen's University Belfast
Career Start Year 1997
Number of shared co-authors 12
Arul M Chinnaiyan
University of Michigan Medical School.
Career Start Year 1993
Number of shared co-authors 24
Gyorgy Petrovics
Henry Jackson Foundation for the Advancement of Military Medicine (HJF)
Career Start Year 1990
Number of shared co-authors 7
Guido Jenster
Erasmus University Medical Center
Career Start Year 1990
Number of shared co-authors 12
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 25
Martin E Gleave
University of British Columbia
Career Start Year 1987
Number of shared co-authors 29
Tapio Visakorpi
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 1987
Number of shared co-authors 11

Collaborators

Steven P Balk
Beth Israel Deaconess Medical Center and Harvard Medical School
Co-authored papers 32
Shuai Gao
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 24
Housheng Hansen He
Princess Margaret Cancer Center, University Health Network, University of Toronto
Co-authored papers 18
Wanting Han
Center for Personalized Cancer Therapy, University of Massachusetts Boston
Co-authored papers 14
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 7
Adam G Sowalsky
National Cancer Institute
Co-authored papers 6
Myles Brown
Co-authored papers 6
Xiaole Shirley Liu
Co-authored papers 5
Sujun Chen
Princess Margaret Cancer Center/University Health Network
Co-authored papers 5
Yan Gao
Co-authored papers 5
Musaddeque Ahmed
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 5
Huihui Ye
College of Optical Science and Engineering, Zhejiang University
Co-authored papers 5
Elahe A Mostaghel
University of Washington
Co-authored papers 4
Eva Corey
University of Washington School of Medicine
Co-authored papers 4
Philip W Kantoff
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Massimo Loda
Weill Medical College of Cornell University
Co-authored papers 3
Rosina T Lis
National Cancer Institute
Co-authored papers 2
Cheryl H Arrowsmith
University of Toronto
Co-authored papers 2
Nathanael S Gray
Harvard Medical School
Co-authored papers 2
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 2
Ilsa Coleman
Fred Hutchinson Cancer Center
Co-authored papers 2
Yi Liang
Princess Margaret Cancer Centre, University Health Network
Co-authored papers 2
Haiyang Guo
the Second Hospital, Cheeloo College of Medicine, Shandong University
Co-authored papers 1
Timothy R Rebbeck
Center for Cancer Equity and Engagement, Dana-Farber/Harvard Cancer Center
Co-authored papers 1
Lewis C Cantley
Co-authored papers 1
Brian Li
Mid & South Essex NHS Foundation Trust
Co-authored papers 1
Robert L Vessella
University of Washington
Co-authored papers 1
Amina Zoubeidi
University of British Columbia
Co-authored papers 1
James E Bradner
Co-authored papers 1
Muhammad B Ekram
Louisiana State University
Co-authored papers 1
Release 1.2